search
Back to results

Effectiveness of a Brain-Computer Interface Based System for Cognitive Enhancement in the Normal Elderly (3ECog)

Primary Purpose

Alzheimer's Disease, Mild Cognitive Impairment, Age-Related Cognitive Decline

Status
Completed
Phase
Phase 1
Locations
Singapore
Study Type
Interventional
Intervention
BrainPalTM
Sponsored by
Duke-NUS Graduate Medical School
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alzheimer's Disease

Eligibility Criteria

60 Years - 70 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Age range between 60-70 years old
  2. Clinical Dementia Rating (CDR) of 0.5*
  3. Geriatric Depression Scale (GDS) of 9 and below
  4. Mini-Mental State Examination of 24 and above*
  5. Chinese ethnicity
  6. Literate in English and/or Chinese
  7. Able to travel to study site independently

    • In the case of conflicting CDR and MMSE scores, MMSE scores will supersede CDR scores.

Exclusion Criteria:

  1. Any known neuropsychiatric disorders (such as epilepsy or mental retardation)
  2. Involvement in another research study (aside from SLAS)

Sites / Locations

  • Duke-NUS Graduate Medical School

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

Intervention

Wait-List Control

Arm Description

Subjects will undergo the BrainpalTM intervention for 24 sessions over the span of 8 weeks. Each session will take 30-minute to complete. The intervention group will undergo the BrainpalTM treatment in the first 8 weeks of the trial.

The waitlist control will start their 8 week treatment after the completion of the intervention group from week 9 onwards. They will undergo the BCI intervention for 24 sessions over the span of 8 weeks.

Outcomes

Primary Outcome Measures

Total Score on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
The Total Score on RBANS reflects the neurocognitive status of the participant by summing five index/domain scores. The domains are Immediate Memory, Visuospatial/Constructional, Language, Attention, and Delayed Memory.

Secondary Outcome Measures

Number of Adverse Events reported by participants on the Safety Measurement Form
The Safety Measurement Form will be completed at the start of every BCI intervention visit (except the first visit). It will collect information on any safety concerns and/or side effects experienced by the participant since their last BCI intervention visit.
Usability Measurement
The usability measurement collects feedback on the acceptability and usability of the BCI intervention program to improve user satisfaction in future trials.

Full Information

First Posted
May 17, 2012
Last Updated
July 24, 2014
Sponsor
Duke-NUS Graduate Medical School
Collaborators
Agency for Science, Technology and Research, National University of Singapore, Singapore Clinical Research Institute, Singapore General Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01661894
Brief Title
Effectiveness of a Brain-Computer Interface Based System for Cognitive Enhancement in the Normal Elderly
Acronym
3ECog
Official Title
Effectiveness of a Brain-Computer Interface Based System for Cognitive Enhancement in the Normal Elderly
Study Type
Interventional

2. Study Status

Record Verification Date
July 2014
Overall Recruitment Status
Completed
Study Start Date
April 2012 (undefined)
Primary Completion Date
April 2014 (Actual)
Study Completion Date
April 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Duke-NUS Graduate Medical School
Collaborators
Agency for Science, Technology and Research, National University of Singapore, Singapore Clinical Research Institute, Singapore General Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary objective is to examine the efficacy of 8-weeks of a locally developed brain-computer interface based system (BrainpalTM)intervention for improving attention and memory in normal elderly. We hypothesize that elderly who have completed the training program will have significant improvement in their attention and memory compared to the controls, based on the Repeatable Battery for the Assessment of Neuropsychological Status.
Detailed Description
The world population has reached an unprecedented seven billion, with global population ageing increasing at a greater rate than total population growth. Between 1998 and 2030, the proportion of persons aged 65 years and over in Singapore will grow by about 3% annually compared to 1.0-1.3% in some developed nations. Specific cognitive deficits like inattention, dysexecutive functioning, and processing speed decline may affect a number of quality of life domains. Concurrent with these statistics, the maintenance of the highest possible level of cognitive functioning for as long as possible has become an important goal of aging successfully. To contribute to the realization of this goal we propose to conduct a wait-list control pilot trial to examine the efficacy and safety of BrainpalTM for cognitive enhancement in the normal elderly. BrainpalTM uses a technology which analyzes brain waves captured through an electroencephalogram to determine the participants' state of attention. The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention. BrainpalTM may represent one alternative means to enhance cognitive abilities and to slow down cognitive decline in the normal elderly. If demonstrated to be efficacious, this therapy may even help to delay the onset of dementia. In addition, the rate of cognitive decline during the course of AD is possibly influenced by not only environmental but also genetic factors. To date, several genes, such as apolipoprotein E (APOE) and TOMM40 (translocase of outer mitochondrial membrane 40 homologue), have been identified to be probable genetic risk markers for AD. These genes have been shown to play a role in disease onset as well as rates of cognitive decline. For instance, studies have shown APOEε4 allele carriers to be associated with earlier and faster cognitive decline. Therefore, we propose to analyse if there is any relationship between the genetic profiles of our participants and their performance in the BrainpalTM training program.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Alzheimer's Disease, Mild Cognitive Impairment, Age-Related Cognitive Decline, Dementia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
82 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intervention
Arm Type
Active Comparator
Arm Description
Subjects will undergo the BrainpalTM intervention for 24 sessions over the span of 8 weeks. Each session will take 30-minute to complete. The intervention group will undergo the BrainpalTM treatment in the first 8 weeks of the trial.
Arm Title
Wait-List Control
Arm Type
No Intervention
Arm Description
The waitlist control will start their 8 week treatment after the completion of the intervention group from week 9 onwards. They will undergo the BCI intervention for 24 sessions over the span of 8 weeks.
Intervention Type
Device
Intervention Name(s)
BrainPalTM
Other Intervention Name(s)
Brain-Computer Interface
Intervention Description
Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. It is a technology that enables people to interact with computers through their thoughts. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. The BCI system will take EEG recordings from the prefrontal cortex to determine the participants' state of attention with high specificity. The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention.
Primary Outcome Measure Information:
Title
Total Score on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
Description
The Total Score on RBANS reflects the neurocognitive status of the participant by summing five index/domain scores. The domains are Immediate Memory, Visuospatial/Constructional, Language, Attention, and Delayed Memory.
Time Frame
Comparison in the change of RBANS total score from baseline (Week 1) to post-treatment (Week 8) in Intervention Group versus Wait-List Control group
Secondary Outcome Measure Information:
Title
Number of Adverse Events reported by participants on the Safety Measurement Form
Description
The Safety Measurement Form will be completed at the start of every BCI intervention visit (except the first visit). It will collect information on any safety concerns and/or side effects experienced by the participant since their last BCI intervention visit.
Time Frame
The duration of 8 weeks of intensive BCI intervention sessions
Title
Usability Measurement
Description
The usability measurement collects feedback on the acceptability and usability of the BCI intervention program to improve user satisfaction in future trials.
Time Frame
Before a subject exits from the study, including completion of the protocol and withdraw of consent
Other Pre-specified Outcome Measures:
Title
Relationship between genetic profile of participants and their performance on the BrainpalTM training program
Description
Blood samples will be collected from each subject for DNA extraction. The samples will be used to generate a genetic profile for each subject. The presence or absence of genes of interest (i.e. TOMM40 and APOEε4)on a subject's genetic profile will then be associated with his or her corresponding performance on BCI, as measured by his or her RBANS scores.
Time Frame
After the BrainpalTM training program is completed

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age range between 60-70 years old Clinical Dementia Rating (CDR) of 0.5* Geriatric Depression Scale (GDS) of 9 and below Mini-Mental State Examination of 24 and above* Chinese ethnicity Literate in English and/or Chinese Able to travel to study site independently In the case of conflicting CDR and MMSE scores, MMSE scores will supersede CDR scores. Exclusion Criteria: Any known neuropsychiatric disorders (such as epilepsy or mental retardation) Involvement in another research study (aside from SLAS)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tih Shih Lee, MD, PhD
Organizational Affiliation
Duke-NUS Graduate Medical School
Official's Role
Principal Investigator
Facility Information:
Facility Name
Duke-NUS Graduate Medical School
City
Singapore
ZIP/Postal Code
169857
Country
Singapore

12. IPD Sharing Statement

Citations:
PubMed Identifier
24260218
Citation
Lee TS, Goh SJ, Quek SY, Phillips R, Guan C, Cheung YB, Feng L, Teng SS, Wang CC, Chin ZY, Zhang H, Ng TP, Lee J, Keefe R, Krishnan KR. A brain-computer interface based cognitive training system for healthy elderly: a randomized control pilot study for usability and preliminary efficacy. PLoS One. 2013 Nov 18;8(11):e79419. doi: 10.1371/journal.pone.0079419. eCollection 2013.
Results Reference
derived

Learn more about this trial

Effectiveness of a Brain-Computer Interface Based System for Cognitive Enhancement in the Normal Elderly

We'll reach out to this number within 24 hrs